Moderna‘s (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company’s revenue, earnings, and stock price have been moving in the wrong direction for the past three years, a period during which the biotech has lost 85% of its value.
Despite what it seems, though, Moderna has made clinical and regulatory progress. If that continues and the company’s plans pan out, it could deliver excellent returns to investors who initiate positions now. Let’s find out whether this scenario is realistic for Moderna.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
Though we are no longer in a state of extreme emergency, COVID-19 is still a problem. Thousands of people continue to get sick, become hospitalized, and die. That’s especially the case with those who are at a higher risk from the disease, including seniors and people with some pre-existing conditions. So, there remains a market for Moderna’s COVID-19 vaccine, although the demand has fallen off a cliff since 2021. In the third quarter, Moderna reported $1.9 billion in revenue, roughly flat compared to the year-ago period.
On the bottom line, the biotech reported net earnings per share of $0.03 compared to a net loss of $9.53 recorded in the year-ago period. Moderna’s sales were almost entirely from Spikevax, its coronavirus vaccine. It also had a 40% share of the U.S. commercial coronavirus vaccine market. Moderna will likely remain a leader in this space for the next five years.
In March, Moderna earned approval for a vaccine for the respiratory syncytial virus (RSV), mRESVIA. In Q3, this product generated just $10 million in sales. That’s not much, but Moderna has more tricks up its sleeves. In June, it reported positive phase 3 results for a combination COVID/flu vaccine. Moderna’s late-stage pipeline also features candidates for the cytomegalovirus (CMV), a stand-alone flu candidate, a potential norovirus vaccine, and a personalized cancer vaccine.
Some of these products look promising. There are currently no approved vaccines for the CMV or the norovirus. Moderna’s candidates could be the first or at least among the first. Furthermore, consider Moderna’s personalized cancer vaccine, which it is developing in collaboration with Merck. In a phase 2b study in melanoma patients, this candidate, combined with Merck’s cancer drug Keytruda, decreased the risk of disease recurrence or death by 49% and the risk of metastasis or death by 62% compared to Keytruda alone after 34.9 months of follow-up.
Moderna should release some data from its late-stage candidates through the next year. However, the company’s pipeline extends beyond that. Moderna has several more programs in phase 1 and 2 studies. From cancer to Lyme disease to HIV, the company is going after many targets, including some very challenging ones. They won’t all pan out. No biotech company has a 100% success rate. But Moderna could transform its lineup over the next five years.
Moderna’s shares aren’t far off from their 52-week low. And at these levels, my view is that the company is worth investing in. Sure, its coronavirus franchise is no longer as successful as it once was, but with the approval of newer products, including its combined COVID/flu vaccine, its RSV product, etc., Moderna’s revenue growth will improve soon enough. Moreover, Moderna’s success so far has proven the value of its platform. mRNA vaccines are faster to manufacture than traditional ones.
That’s a significant advantage. And given the company’s vast pipeline, we can expect many more successes. The market may have made a mistake by sending Moderna’s shares to stratospheric heights back in 2020 and 2021, but it is undervaluing the company’s prospects a bit too much now. That means there is plenty of upside potential for patient investors.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $334,266!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $46,976!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $479,727!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of December 16, 2024
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
